Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tucatinib and Trastuzumab With Total Neoadjuvant Therapy for Locally Advanced HER2-amplified Rectal Adenocarcinoma
NCT05672524Phase 2Recruiting
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Dec 2022
- Primary completion
- Jul 2027
- Modality
- Antibody Conjugates, Monoclonal Antibodies, Engineered Antibody Formats
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucatinib and trastuzumab in rectal adenocarcinoma, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Clinical Complete Response at 21 weeks. Started Dec 2022; status: recruiting.
02
Drugs
tucatinibtrastuzumab
03
Conditions
rectal adenocarcinoma
Beyond the preview
Go deeper on NCT05672524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05672524.